title: Mucosal melanoma of the head and neck.
abstract: Two hundred and fifty-nine patients with mucosal melanoma of the head and neck were reviewed. The data of these patients were obtained from the records of the Department of Head and Neck Oncology at the University of Liverpool and from the Merseyside and Cheshire Cancer Registry. Survival curves were constructed using the life table method and differences were investigated by the Log Rank Test. Prognostic factors were further analysed by Cox's proportional hazards model. Melanomas of the nasal cavities and sinuses accounted for 69%; 22% occurred in the oral cavity and 9% in the pharynx, larynx and upper oesophagus. In 49% treatment was by wide local resection and in 8% by irradiation. Thirty-six per cent had combined modalities of treatment. Primary site recurrence occurred in 52% and 36% developed nodal recurrence. The tumour specific survival at 5 years was 45% at 10 years 28%, at 20 years 17% and closely resembled the observed survival. Young male patients tended to have a favourable prognosis as did those treated surgically. Radiotherapy on its own was ineffective. Amelanotic melanoma had a particularly poor survival. Whereas site had no effect on survival. The study confirms the poor prognosis of mucosal melanoma of the head and neck. Young patients should be offered radical surgical treatment combined with radical radiotherapy if feasible as this offers the best chance of cure.
authors.affiliation: Department of Otolaryngology, University of Liverpool, UK.
authors.forename: V
authors.initials: V
authors.lastname: Nandapalan
authors.forename: N J
authors.initials: NJ
authors.lastname: Roland
authors.forename: T R
authors.initials: TR
authors.lastname: Helliwell
authors.forename: E M
authors.initials: EM
authors.lastname: Williams
authors.forename: J W
authors.initials: JW
authors.lastname: Hamilton
authors.forename: A S
authors.initials: AS
authors.lastname: Jones
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D004739:England / Q000453:epidemiology; D004938:Esophageal Neoplasms / Q000453:epidemiology; D005260:Female; D006258:Head and Neck Neoplasms / Q000453:epidemiology* / Q000401:mortality; D006801:Humans; D007822:Laryngeal Neoplasms / Q000453:epidemiology; D015993:Life Tables; D016014:Linear Models; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000453:epidemiology* / Q000401:mortality / Q000556:secondary; D018328:Melanoma, Amelanotic / Q000453:epidemiology / Q000401:mortality; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000453:epidemiology; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009669:Nose Neoplasms / Q000453:epidemiology; D010255:Paranasal Sinus Neoplasms / Q000453:epidemiology; D010610:Pharyngeal Neoplasms / Q000453:epidemiology; D011379:Prognosis; D016016:Proportional Hazards Models; D012042:Registries; D012189:Retrospective Studies; D012737:Sex Factors; D015996:Survival Rate